The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.
As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.
Visby Medical’s at-home diagnostic, which can be purchased without a prescription, tests for chlamydia, gonorrhea and ...
The U.S. Food and Drug Administration granted marketing authorization for the first home-based, nonprescription diagnostic test for chlamydia, gonorrhea, and trichomoniasis in women, the agency ...
US FDA grants fast track designation to Sanofi’s mRNA vaccine candidate for prevention of chlamydia infection: Paris Friday, March 28, 2025, 12:00 Hrs [IST] The US Food and Drug ...
The US Food and Drug Administration (FDA) has granted marketing authorization for the first at-home test to diagnose ...
Health and Me on MSN1d
FDA Approves At-Home Test For Three STIs In WomenThe US Food and Drug Administration has approved a single-use at-home test which can detect three STIs in women. Read on to ...
The FDA reviewed this test under the FDA’s De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk ...
The FDA has approved the first at-home, nonprescription test for chlamydia, gonorrhea, and trichomoniasis in women. The Visby ...
The U.S. Food and Drug Administration (FDA) has granted marketing authorization to Visby Medical for its Women’s Sexual Health Test, the first home diagnostic test for chlamydia, gonorrhea, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback